| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2528430 | Clinical Therapeutics | 2011 | 22 Pages |
Abstract
This analysis is subject to the usual limitations of cost-effectiveness models, which combine assumptions and data from multiple sources. Nevertheless, based on the assumptions used herein, the present model suggests that ZOL increases QALYs and is cost saving and/or cost effective compared with placebo in patients with NSCLC in France, Germany, the United Kingdom, Portugal, and the Netherlands.
Related Topics
Health Sciences
Medicine and Dentistry
Medicine and Dentistry (General)
Authors
Avani D. PhD, John A. BA, Marc F. MSc, MA, Satyin MSci, MBA,